There is increasing uncertainty over the potential benefits and harms of volume expansion in paediatric and adult critical care settings. In addition, there are increasing numbers of reports of adverse effects and association with RBC transfusions in neonates, including transfusion-associated necrotizing enterocolitis. Preterm infants <28 weeks' gestation in particular are likely more vulnerable to volume shifts and changes in blood pressure due to their unique physiology. This review paper will provide an overview of the current evidence base supporting the use of RBC transfusion thresholds and the use of fluid bolus therapy in neonates. We will argue that enhanced data collection and collaborations through neonatal networks, development of international consensus definitions of transfusion adverse effects and associations, as well as haemodynamic compromise in neonates, are needed to further advance research in these areas.
Introduction
Neonates are an intensively transfused group of recipients. In Australia, in 2013, 309 489 babies were born with 307 277 live births and 2191 stillborn [1] . Of live births, 43 159 (14%) of neonates were admitted to neonatal units, with the majority (75%) admitted due to prematurity (born at <37 +0 weeks' gestation). There has also been a major change in the characteristics of admissions to the neonatal intensive care unit (NICU) over the last few decades. Infants born at 27 or 28 weeks' gestation that 20 years ago would have been recognized at the limits of medical care are now admitted with an expectation of discharge home. The EPICure studies found increases in survival for extremely preterm babies from 40% in 1995 to 53% in 2006. However, no differences in rates of morbidities were reported, despite advances in neonatal care over this time [2] . At initial discharge home, 68% (n = 705) of survivors in the EPICure studies had chronic lung disease (CLD), 13% (n = 135) had evidence of serious abnormality on cerebral ultrasonography and 16% (n = 166) had laser treatment for retinopathy of prematurity (ROP). More needs to be done to improve the longer-term outcomes of the increasing numbers of these extremely preterm neonates surviving each year. This includes ensuring that supportive care including fluid and nutrition, respiratory support and use anti-microbials are given only when the benefits outweigh the harms, and where we have a good understanding of the long-term consequences. An additional consideration is, as perhaps expected, the evidence base for many practices of neonatal care is poorly developed. Randomized trials for many otherwise accepted practices remain to be undertaken [3] . This raises questions about how far practices underpinned by trials in other patient settings should be extrapolated to neonatal care.
All these issues apply to neonatal red blood cell (RBC) transfusion therapy and fluid bolus therapy and will be discussed in more depth in this review article. For example, there has been a paradigm shift in transfusion practice to manage adult patients with major trauma bleeding with greater emphasis on empiric use of plasma alongside RBCs. Catastrophic bleeding is rare in neonates but does occur in some settings including feto-maternal haemorrhage and placental abruption.
The practice of red blood cell transfusion in preterm and term neonates
In neonatal units, RBC transfusions are most often undertaken to manage anaemia of prematurity (AOP) [4] . Anaemia of prematurity is a multi-factorial condition defined by early, significant anaemia in the context of phlebotomy blood losses, lower erythropoietin (EPO) production, decreased foetal haemoglobin survival and a limited bone marrow response [5] . Recognition of AOP relies upon a combination of non-specific clinical symptoms of anaemia and haemoglobin or haematocrit levels [6, 7] . However, there is no evidence exists that there is a haemoglobin or haematocrit threshold where inadequate tissue oxygenation (critical anaemic hypoxaemia) definitively occurs in infants of any gestational age. The more premature an infant is, the more likely they are to have AOP and consequent RBC transfusions. In term newborns, however, there is a large variation in comorbidities that may led to anaemia, including foetal-maternal haemorrhage, congenital red cell diseases, alloimmune disorders, congenital cardiac disease requiring surgery and sepsis [4] . This makes it a challenge to extrapolate findings from RBC transfusion studies in preterm infants to term infants, and vice versa.
Preterm neonates
At present, the majority of published literature around usage patterns of blood products in neonatal units was published in the 1990s and is based upon data obtained from practice surveys [8, 9] . However, more contemporary studies are emerging. A retrospective cohort study of preterm neonates born at less than 30 weeks' gestation and admitted to participating neonatal units in the Canadian Neonatal Network from 2004 to 2012 was conducted to evaluate blood product usage [10] . It found blood product use remains at a very high frequency in preterm neonates born at less than 30 weeks' gestation. Of the 14 868 infants included, 8252 (56%) received at least one RBC transfusion. Three time epochs (2004-2006, 2007-2009 and 2010-2012) were examined and compared, revealing a trend towards fewer RBC transfusions among neonates born at 26-29 weeks' gestation. Use remained unchanged or increased for neonates born at 23-25 weeks' gestation. This study was not able to provide information regarding specific indications for transfusions; changes in institutional transfusion guidelines and adverse transfusion reactions are not part of the data collection process for the network. The National Comparative Audit of the Use of Red Blood Cells in Neonates and Children from the National Health Service (NHS) in the United Kingdom [4] found the median and interquartile rate of gestational age at birth of those receiving at least one RBC transfusion was 27 (26) (27) (28) (29) (30) weeks, n = 1194, and the majority (81%; 971) of initial transfusions were given to infants born at <32 weeks' gestational age. The majority of these RBC transfusions were prescribed for anaemia, with (60%) or without (21%) symptoms. The majority of infants (75%) were either mechanically ventilated or on continuous positive airway pressure (CPAP) at the time of their initial RBC transfusion.
Red blood cell transfusion practice and evidence base
A systematic review examining the safety and efficacy of RBC transfusions in neonates found 27 randomized controlled trials [11] . The authors noted that while it might appear that the total number of identified trials represents a substantial evidence base to inform neonatal transfusion practice, it is negated by methodological limitations of the included trials [11] . Only three out of the included 27 trials compared RBC transfusion with no transfusion (or placebo) and they enrolled less than 100 patients in total. The majority of included trials compared different schedules, doses or products for RBC transfusion. A Cochrane review further summarized the data examining liberal (high) compared to restrictive (low) RBC transfusion thresholds and found no evidence that either strategy had an effect on mortality, major morbidities or on survival without major morbidity in preterm infants ≤1500 grams. It included three published studies [12] [13] [14] and one unpublished [15] . Similar restrictive transfusion thresholds were used for all included studies and are shown in Table 2 . Safety at haemoglobin levels below these limits in Table 1 has not been evaluated. Included in this Cochrane review were the two widely known and cited transfusion RBC thresholds studies in neonates ( Table 2 ). The first is by Bell et al. [13] , which included 100 infants, and it was designed to examine numbers of RBC transfusions and donor exposures per infant. The second is the Premature Infants in Need of Transfusion (PINT) study [12] , including 451 infants, and it was designed to assess the composite primary outcome of death before hospital discharge or survival with any of severe retinopathy, bronchopulmonary dysplasia or brain injury on cranial ultrasound. No differences in the composite primary outcome were found between low and high transfusion threshold groups in the PINT study. The Bell study [16] also did not find any differences in significant morbidities or mortality; however, as this study was primarily designed to examine differences in transfusion numbers between groups, it is challenging to draw any conclusions from this. It is also challenging to find out the exact amount of RBCs administered in studies as the haematocrit of the neonatal product is not uniform.
Longer-term follow-up of these studies [16, 17] found conflicting results in regard to neurodevelopmental outcome; however, neither study was designed to examine this outcome. The longer-term follow-up to the PINT study suggested that higher haemoglobin thresholds may benefit longer-term neurodevelopmental outcomes assessed at 18-24 months of age [16] . The longer-term follow-up to the Bell study found more liberal RBC transfusions were associated reduced brain volumes at 12 years of age, however, only 44 of the original 100 trial participants were followed [17] , limiting the value of interpretation of the findings. The main similarity between these two trials was the volume for each transfusion at 15 ml/kg with significant differences in most other areas, including the study primary outcomes, included birthweights, transfusion thresholds and transfusion algorithms [12, 13] . It is important to note that neither study was statistically powered to assess longterm neurodevelopmental outcomes. In addition, these trials of RBC transfusion thresholds for preterm infants did not specify the prevailing oxygen saturation targeting strategy, reducing their applicability to neonatal care today. Consequently, the interpretation of these two trials has varied, with some highlighting the lack of short-term benefit of liberal transfusion thresholds, and others concerned that there might be long-term neurodevelopmental harms of a restrictive strategy [18] [19] [20] .
Term infants
For term infants, there is even less evidence to guide thresholds for RBC transfusion. There is only one study that provides some guidance, the Transfusion Strategies for Patients in Pediatric Intensive Care Units (TRIPICU) study [21] . This study showed no difference in oxygenation markers, duration of ventilation, cardiac dysfunction and length of hospital stay when critically ill infants and children were transfused at thresholds of 70 g/l compared to 95 g/l. However, this study included only 11 neonates less than 28 days of age in the restrictive arm and eight in the liberal arm, out of a total study population of 637. The study also had relatively broad exclusion criteria. Neonates less than 40 weeks' gestational age or <3 kg, those <3 days of age, those with uncorrected cyanotic heart disease, severe thrombocytopenia, acute blood loss, hypoxaemia, on dialysis, severe thrombocytopenia, a decision to withhold or withdraw critical care, a predicted survival of <24 h or needing extracorporeal membrane oxygenation were all excluded. In view of the small numbers of neonates included in this study and the broad exclusion criteria, the optimal haemoglobin threshold to transfuse term neonates at remains elusive. The TRIPICU study remains the only large pragmatic trial in young haemodynamically stable children, although term infants formed a small number of participants; the overall findings of the trial and long list of reasons for exclusions support the need for new research to address optimal transfusion policies in all age groups including unstable patients frequently presenting with comorbidities.
Ongoing clinical trials
At present, there is insufficient evidence to either accept or reject a restrictive or liberal RBC transfusion strategy in preterm or term neonates. However, there is a need to identify the potential benefits or harms that may arise from either strategy, and further studies are underway in preterm infants only. Two clinical trials, the Thresholds on Neurocognitive Outcome of extremely low birthweight infants (ETTNO) [22] and the Transfusion of Prematures trial (TOP) [23] examining the short-and longer-term neurodevelopmental outcomes to 24 months of corrected age in extremely low birthweight infants randomized to liberal or restrictive RBC transfusion thresholds are underway. These trials may provide information to guide neonatal transfusion practice and longer-term outcomes related to transfusion. No trials are underway to examine transfusion thresholds in term infants.
Adverse effects and associations of neonatal RBC transfusion
The previously discussed randomized trials provided some information on the balance of benefits and risks with RBC transfusion. There is also a much broader literature including observational studies, with or with comparator groups that informs any discussion of harm. Associations between neonatal RBC transfusions and increased mortality [24, 25] as well as significant morbidities such as necrotizing enterocolitis (NEC) [26] , intraventricular haemorrhages (IVH) [27] , ROP [28] , CLD [29] have all been discussed at times and reported in the literature. One method to understand these risks, which may be low frequency, is to explore findings from haemovigilance systems. Data published from the Serious Hazards of Transfusion (SHOT) scheme from the United Kingdom highlights that transfusion reactions, usually observed in adults, do occur in neonates [30] . However, there is likely underreporting and lack of recognition of adverse transfusion effects and associations in neonates due to intercurrent illness and lack of awareness of clinicians. SHOT estimates the rates of an adverse outcome to be 18:100 000 RBCs issued for children younger than 18 years and 37:100 000 for infants younger than 12 months compared with 13:100 000 for adults [30] . This demonstrates there are a disproportionate number of transfusion errors in the neonatal and paediatric age groups. Reporting to haemovigilance systems may be improved by the development of neonatal and paediatricspecific definitions of adverse transfusion effects and associations, although this is likely to be challenging due to the nature of neonatal morbidities. A further systematic review and meta-analysis reported a broad synopsis of all reported risks to better understand the clinical adverse effects and associations attributed to neonatal RBC transfusions. Studies were classified into two groups, in which there was a difference in transfusion numbers and/or volume between groups to compare liberal versus restrictive RBC transfusion practices. Liberal transfusion practice was defined as one group receiving a greater volume and/or number of RBC transfusions compared with the comparison group (restrictive transfusion practice). This allowed a comparison between the outcomes of infants who were exposed to restrictive or liberal RBC transfusion practice. The review did not find any differences in clinical outcomes between restrictive and liberal neonatal RBC transfusion practices. Metaanalyses of studies that included a comparator group did not identify any consistent differences in mortality during initial hospitalization, CLD, NEC, IVH and bacterial contamination/sepsis between neonates exposed to higher or lower volumes of RBC transfusions, in either randomized or nonrandomized studies. These findings are contrary to current opinion about the risks of transfusion in the neonatal population [31, 32] . Reason may include limitations of much of the primary study evidence, which the systematic review is based on, needs to be acknowledged. Very few studies included in the review provided clear definitions of the different potential adverse effects related to RBC transfusion.
Kirpalani and Zupancic undertook a more focussed systematic review and a meta-analysis [33] of the published literature on the association between transfusions in newborns and the occurrence of NEC. Necrotizing enterocolitis is a rare but devasting disease that affects preterm infants and is associated with high rates of morbidity and mortality. The authors found that the direction of effect of RBC transfusions on NEC (more transfusions show lower NEC) as demonstrated in randomized trials was opposite to that seen in observational studies (transfusions are associated with NEC). A recent study by Patel et al. [34] found that severe anaemia, not RBC transfusion, was associated with an increased risk of NEC. The authors suggest that prevention of severe anaemia may be more important than minimizing RBC transfusion alone [34] .
Proposed underlying mechanism of adverse transfusion effects and associations
The proposed mechanism or mechanisms underlying adverse transfusion effects and associations are unclear. A proposed mechanism relates to the modulation of a transfusion recipient's immune system, termed transfusion-related immunomodulation (TRIM) [35] . In the clinical setting of an underlying inflammatory state priming the recipient's immune system, transfusion of allogenic RBC may trigger immune cell activation and related immunomodulation, resulting in frank inflammation. Data are available to support this hypothesis, with increases in interleukin (IL) 1b, IL-8, tumour necrosis factor (TNF) a and monocyte chemoattractant protein-1 observed after allogenic RBC transfusion in preterm infants [36] . These increases also correlated with increases in markers of endothelial activation [36] . This pro-inflammatory reaction may be a manifestation of TRIM. It may partly explain the association between RBC transfusion and the development of NEC, ROP and CLD. However, it should be noted that similar observations have occurred in the adult population and have not be linked with adverse clinical events to date.
Use of blood products and crystalloids for volume expansion in neonates
Another aspect of neonatal transfusion practice includes the use of blood products as a volume expander or fluid bolus. This area is of intense interest in adult and older patients with acute bleeding. Fluid bolus therapy may be used in neonates as part of management of haemodynamic compromise, for example, due to hypotension. However, the volume and type of fluid used, as well as the timing and the indications for fluid boluses are not well described. Types of fluids used to manage suspected haemodynamic compromise in neonates may include crystalloids, most commonly 0Á9% sodium chloride [37] , or blood products including fresh frozen plasma (FFP), albumin and RBCs. As for RBC transfusions, there are key questions about the benefit-risk ratio. Potential adverse effects of all types of fluid boluses in neonates include volume overload, dilutional coagulopathy, hypothermia and electrolyte disturbances. In addition, particular fluids may cause specific complications, such as RBC and plasma-associated transfusion reactions [26, 38] , or 0Á9% sodium chloride-induced hyperchloraemic metabolic acidosis. Observational studies suggest dose-related adverse effects of volume overload; in preterm infants, multiple fluid boluses have been associated with increased mortality [39] and intraventricular haemorrhages [40] , whereas lower total fluid intakes in the first week of age were correlated with decreased chronic lung disease and mortality [41, 42] . The Fluid Expansion as Supportive Therapy (FEAST) study found increased 48-hourly mortality in critically ill children randomized to receive fluid bolus therapy [43] .
Fluid bolus therapy: underlying principles
Due to our current lack of ability to predict which, and whether, neonates may benefit from a fluid bolus, standard practice in neonatal medicine is to empirically administer a fluid bolus to suspected haemodynamically compromised infants. Then, the effect on cardiac output or other variables, such as acid-base and/or lactate, to draw conclusions about benefit at the tissue and cellular level is evaluated. Repeated fluid boluses may cause harm through increases in fluid load, possibly inducing harm [44] . In a preload responsive individual whose heart is operating at the steep portion of the Frank-Starling curve, additional volume will increase stroke volume and increase cardiac output [45] . The inferred consequence is improved tissue perfusion, in turn improving cell and organ function. These are the physiologic principles on which fluid bolus therapy is based. It is supported by previous data revealing an increase in cardiac output postfluid bolus in preterm infants [46] .
Evidence base for fluid bolus therapy in preterm infants
There are no randomized studies primarily designed to examine fluid bolus compared to no fluid bolus in preterm infants with haemodynamic compromise [47] . Several studies [48] [49] [50] [51] [52] published between 1976 and 2000 comparing fluid bolus (volume expansion) to no fluid bolus in preterm infants are available; however, the majority of included infants did not have signs of haemodynamic compromise. Meta-analysis of these studies found no differences in clinical outcomes, including mortality, grade 3-4 intraventricular haemorrhage and neurodevelopmental impairment [53] . The largest, and bestknown study examining the use of fluid boluses in preterm neonates, is the Northern Neonatal Nursing Initiative (NNNI) Trial Group study (n = 776) [52] . The study was designed to determine whether early volume expansion, including with FFP administration, would reduce morbidity and mortality in infants <32 weeks' gestation. Prophylactic FFP (20 ml/kg followed by 10 ml/kg after 24 h); or a similar volume of an inert gelatine plasma substitute; or control management with a maintenance infusion of 10% dextrose were compared. The study found no effect of use of FFP as early volume expansion on cranial ultrasound abnormalities or mortality prior to initial discharge. In the 2-year follow-up study [54] , no significant differences between groups in severe disability or mortality were reported. The study published in 1996 and likely does not reflect current clinical practice, limiting its relevance [55] . Critically, volume expansion was used 'prophylactically' as opposed as part of management of haemodynamic compromise, limiting the conclusions able to be drawn from its findings. As a consequence, this study does not provide information on whether or not fluid boluses are beneficial in preterm infants with haemodynamic compromise.
Fluid bolus therapy in preterm and term neonates
As part of an initiative to understand the practice of fluid bolus therapy in both preterm and term neonates, a first multi-centre international cross-sectional observation of fluid bolus therapy for the management of suspected haemodynamic compromise in neonatal units was undertaken and presented in abstract form recently [56] . This study was an international, multi-centre, cross-sectional study undertaken at 41 neonatal units in Australasia, North America and Europe. Units were recruited through neonatal research networks and specialty societies, as well as through personal communications directed by the main study investigators. Participating neonatal units collected data in blocks of 5 continuous days in 2-3 blocks for a minimum of 10 days and up to a maximum of 15 days per unit. The study found fluid boluses are administered to 1-2% of neonates in highly resourced countries. The most common type of fluid used was 0Á9% sodium chloride, and the most common dose 10 ml/kg and most common infusion time was over 30 min. The most frequent indication was low blood pressure, followed by decreased perfusion on clinical assessment, then metabolic acidosis, and an elevated lactate level. This study demonstrated that is feasible for neonatal units around the world to collaborate successfully and provide data around a common clinical practice. By collecting data in the blocks of 10-15 days across a large number of units, it allowed for a greater representation of clinical practice. The information provided by this study characterized a level of uncertainty about this clinical practice, which will be helpful to refer to when preparing for further studies in this area. The ongoing use of fluid bolus therapy in neonates, as described by this study, implies that many healthcare professionals assume fluid bolus therapy is beneficial to both preterm and term infants. There were wide variations in rate and reasons for fluid administration in the different units throughout the study period. Given the lack of evidence of effectiveness and additional concerns about harm, these variations are concerning. This study supports the need for multi-centre international research collaborations.
Key implications for practice
There is value in health care from reducing practice variation. Even while the evidence base for RBC transfusion and fluid bolus therapy is limited, as it is in neonates, development and used of clinical guidelines is still recommended [57] . As further research in these areas are published, new knowledge can be disseminated and implemented through the update of these guidelines.
Research priorities
As recently highlighted by Goel and Josephson [58] , one of the biggest impediments to advancement of neonatal transfusion research is that there are no registries or networks that include neonatal RBC transfusion relevant data with outcome or donor linkage to recipients in sufficient detail. Multi-centre international research collaborations are also required to definitively determine the risk of RBC transfusion in neonates. Before this occurs, standardization of definitions of adverse effects and associations of RBC transfusion in neonates, through an international consensus, is required. A continued focus on retrospective studies that report potential associations between RBC transfusion and the development of NEC, a devastating but rare disease, may have diverted attention from higher quality study designs to establish the real risks of neonatal transfusion.
Conclusion
This review provided a number of insights into neonatal transfusion practice and fluid bolus therapy. Future directions include enhanced data collection and collaborations through neonatal networks, development of international consensus definitions of transfusion adverse effects and associations, as well as haemodynamic compromise in neonates and the need for further clinical studies in this vulnerable patient group.
